Phaseline

Companies › BioVersys SAS

BioVersys SAS: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 2 Phase 3, 1 Phase 1, 1 Phase 4, 1 Phase 2; Infectious disease, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rifabutin (BV100)
Bacterial DNA-directed RNA polymerase inhibitor
–Phase 3Hospital Acquired Bacterial Pneumonia (HABP); Healthy Adult Participants; Mycobacterium Abscessus Lung Disease; Prosthetic Infection …Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07514364Rifabutin (BV100)Phase 4Mycobacterium Abscessus Lung DiseaseInfectious diseaseMar 2026
NCT04672525Rifabutin (BV100)Phase 3Prosthetic InfectionInfectious diseaseNov 2026
NCT07580586Rifabutin (BV100)Phase 1Healthy Adult ParticipantsOtherDec 2026
NCT05766267Rifabutin (BV100)Phase 2Tuberculosis, PulmonaryInfectious diseaseDec 2026
NCT07326540Rifabutin (BV100)Phase 3Hospital Acquired Bacterial Pneumonia (HABP)Infectious diseaseDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Meitheal Pharmaceuticals Avenue Therapeutics Freya Biosciences ApS BioAegis Therapeutics Aligos Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.